Abstract
Psoriasis has long been considered a genetic disorder. The first observation that psoriasis is an inherited, familial skin disorder was made in 1957. Extensive epidemiologic evidence and monozygotic twin concordance studies confirmed familial clustering of this chronic inflammatory disease and drove scientific investigation into the genetic basis of psoriasis. Since 1957, the list of psoriasis-associated genetic polymorphisms, including some rare causal mutations, has grown tremendously due to advanced high-throughput genotyping platforms and statistical methods. Nevertheless, the majority of psoriasis patients lack known psoriasis-associated susceptibility loci and the exact molecular mechanisms by which polymorphisms contribute to psoriasis remains poorly understood. Recent work points to a complex interplay between genetics, epigenetics, and the inflammatory signaling networks of skin and immune cell mediators. In contrast, other mutations appear to be causative, such as the recently identified mutations in IL36RN and CARD14, and shed light on new immunologic pathways driving pustular psoriasis. Evidence is also rapidly accumulating for the role of epigenetic changes in psoriasis heritability. The decreasing cost and rapid advancements in genetic technologies in combination with the formation of multi-institutional patient registries will likely result in a better understanding of the “missing heritability” in psoriasis and other complex, multigenic diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535–46.
Brandrup F, Holm N, Grunnet N, et al. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol. 1982;62:229–36.
Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974;109:207–11.
Lonnberg AS, Skov L, Skytthe A, et al. Heritability of psoriasis in a large twin sample. Br J Dermatol. 2013;169:412–6.
Grjibovski AM, Olsen AO, Magnus P, et al. Psoriasis in Norwegian twins: contribution of genetic and environmental effects. J Eur Acad Dermatol Venereol. 2007;21:1337–43.
Russell TJ, Schultes LM, Kuban DJ. Histocompatibility (HL-A) antigens associated with psoriasis. N Engl J Med. 1972;287:738–40.
Tiilikainen A, Lassus A, Karvonen J, et al. Psoriasis and HLA-Cw6. Br J Dermatol. 1980;102:179–84.
Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41:199–204.
Clop A, Bertoni A, Spain SL, et al. An in-depth characterization of the major psoriasis susceptibility locus identifies candidate susceptibility alleles within an HLA-C enhancer element. PLoS One. 2013;8:e71690.
Varla-Leftherioti M. The significance of the women’s repertoire of natural killer cell receptors in the maintenance of pregnancy. Chem Immunol Allergy. 2005;89:84–95.
Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity. 1997;7:753–63.
Hubbard T, Barker D, Birney E, et al. The Ensembl genome database project. Nucleic Acids Res. 2002;30:38–41.
Luszczek W, Manczak M, Cislo M, et al. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol. 2004;65:758–66.
Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet. 2002;31:429–34.
Nelson GW, Martin MP, Gladman D, et al. Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol. 2004;173:4273–6.
Gudjonsson JE, Karason A, Antonsdottir A, et al. Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br J Dermatol. 2003;148:233–5.
Lysell J, Tessma M, Nikamo P, et al. Clinical Characterisation at Onset of Childhood Psoriasis – A Cross Sectional Study in Sweden. Acta Derm Venereol. 2015;95:457–61.
Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627–32.
Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143:1177–82.
Mallbris L, Wolk K, Sanchez F, et al. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study. BMC Dermatol. 2009;9:5.
Fry L, Powles AV, Corcoran S, et al. HLA Cw*06 is not essential for streptococcal-induced psoriasis. Br J Dermatol. 2006;154:850–3.
Ozawa A, Miyahara M, Sugai J, et al. HLA class I and II alleles and susceptibility to generalized pustular psoriasis: significant associations with HLA-Cw1 and HLA-DQB1*0303. J Dermatol. 1998;25:573–81.
Gonzalez S, Martinez-Borra J, Del Rio JS, et al. The OTF3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602. J Invest Dermatol. 2000;115:824–8.
Holm SJ, Carlen LM, Mallbris L, et al. Polymorphisms in the SEEK1 and SPR1 genes on 6p21.3 associate with psoriasis in the Swedish population. Exp Dermatol. 2003;12:435–44.
Feng BJ, Sun LD, Soltani-Arabshahi R, et al. Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet. 2009;5:e1000606.
Knight J, Spain SL, Capon F, et al. Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. Hum Mol Genet. 2012;21:5185–92.
Okada Y, Han B, Tsoi LC, et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet. 2014;95:162–72.
Matthews D, Fry L, Powles A, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet. 1996;14:231–3.
Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994;264:1141–5.
Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet. 1997;6:1349–56.
International Psoriasis Genetics Consortium. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am J Hum Genet. 2003;73:430–7.
Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273–90.
Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44:1341–8.
Xu L, Li Y, Zhang X, et al. Deletion of LCE3C and LCE3B genes is associated with psoriasis in a northern Chinese population. Br J Dermatol. 2011;165:882–7.
Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007;122:201–6.
Hurdayal R, Nieuwenhuizen NE, Revaz-Breton M, et al. Deletion of IL-4 receptor alpha on dendritic cells renders BALB/c mice hypersusceptible to Leishmania major infection. PLoS Pathog. 2013;9:e1003699.
Das S, Stuart PE, Ding J, et al. Fine mapping of eight psoriasis susceptibility loci. Eur J Hum Genet. 2015;23:844–53.
Landry M, Muller SA. Generalized pustular psoriasis. Observations on the course of the disease in a familial occurrence. Arch Dermatol. 1972;105:711–6.
Blumberg H, Dinh H, Trueblood ES, et al. Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation. J Exp Med. 2007;204:2603–14.
Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365:620–8.
Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426–37.
Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and new insights into pathways of skin inflammation: what’s in a name? Arch Dermatol. 2012;148:381–4.
Carapito R, Isidor B, Guerouaz N, et al. Homozygous IL36RN mutation and NSD1 duplication in a patient with severe pustular psoriasis and symptoms unrelated to deficiency of interleukin-36 receptor antagonist. Br J Dermatol. 2015;172:302–5.
Brau-Javier CN, Gonzales-Chavez J, Toro JR. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Arch Dermatol. 2012;148:301–4.
Huffmeier U, Watzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170:202–4.
Rossi-Semerano L, Piram M, Chiaverini C, et al. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics. 2013;132:e1043–7.
Li X, Chen M, Fu X, et al. Mutation analysis of the IL36RN gene in Chinese patients with generalized pustular psoriasis with/without psoriasis vulgaris. J Dermatol Sci. 2014;76:132–8.
Berki DM, Mahil SK, Burden AD, et al. Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris. J Invest Dermatol. 2014;134:271–3.
Li M, Han J, Lu Z, et al. Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris. J Invest Dermatol. 2013;133:2637–9.
Sugiura K, Muto M, Akiyama M. CARD14 c.526G > C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134:1755–7.
Fuchs-Telem D, Sarig O, van Steensel MA, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet. 2012;91:163–70.
Jordan CT, Cao L, Roberson ED, et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet. 2012;90:796–808.
Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90:784–95.
Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014;74:187–92.
O’Connell RM, Rao DS, Baltimore D. microRNA regulation of inflammatory responses. Annu Rev Immunol. 2012;30:295–312.
Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12:861–74.
Pivarcsi A, Stahle M, Sonkoly E. Genetic polymorphisms altering microRNA activity in psoriasis – a key to solve the puzzle of missing heritability? Exp Dermatol. 2014;23:620–4.
Kulkarni S, Qi Y, O’HUigin C, et al. Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease. Proc Natl Acad Sci U S A. 2013;110:20705–10.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hawkes, J.E., Feng, BJ., Duffin, K.C. (2016). Genetics of Psoriasis. In: Adebajo, A., Boehncke, WH., Gladman, D., Mease, P. (eds) Psoriatic Arthritis and Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-319-19530-8_10
Download citation
DOI: https://doi.org/10.1007/978-3-319-19530-8_10
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-19529-2
Online ISBN: 978-3-319-19530-8
eBook Packages: MedicineMedicine (R0)